VERU vs ANPA Comparison

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Rich Sparkle Holdings Ltd is a holding company conducting its operations as a professional specialist in the provision of financial printing services such as printing, typesetting and translation, advisory services including Environmental, Social and Governance (ESG) and internal control reporting services and other services including standalone annual general meeting and extraordinary general meeting supporting service and other standalone services, through its sole operating subsidiary in Hong Kong. Its segments include Financial printing services such as printing, typesetting and translation, Advisory services including Environmental, Social and Governance Report and Other services.